BLMN
Bloomin' Brands, Inc.
BLMN has the edge over LCID overall, supported by stronger valuation and lower modeled downside.
LCID
Lucid Group, Inc.
LCID offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
BLMN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Stable |
BLMN's profitability is currently healthy, and its revenue, cash flow and balance sheet are stable.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
BLMN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 9.3x | $10.12 | — |
| Cheap | 9.8x | $8.08 | -20% |
| Current | 12x | $10.12 | — |
| Fair | 22x | $18.19 | +80% |
| Expensive | 34x | $27.95 | +176% |
Historical ranges are pointers, not guarantees.
BLMN's PE is in its cheap range at 12x. If earnings grow as analysts expect, today's price would be 9.3x next year's earnings.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
BLMN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Stable | |
| Limited | |
| Low |
Analysts expect BLMN's earnings to grow, with its revenue and profitability holding steady. However, they disagree widely on these estimates.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
BLMN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.09 | +33% |
| Q3 2026 | $0.82 | +$1.49 |
| Q2 2026 | $0.31 | +$0.36 |
| Q1 2026 | $0.25 | +$0.28 |
| Q4 2025 | $0.10 | +$1.59 |
| Q3 2025 | -$0.67 | -$0.59 |
| Q2 2025 | -$0.05 | -117% |
| Q1 2025 | -$0.03 | -104% |
| Q4 2024 | -$1.49 | -158% |
BLMN has the edge over LCID on earnings quality, reporting a profit while its opponent remains loss making.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
BLMN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $944.3M | +1.7% |
| Q2 2026 | $1B | +1.3% |
| Q1 2026 | $1.1B | +1% |
| Q4 2025 | $975.2M | +0.3% |
| Q3 2025 | $928.8M | -11% |
| Q2 2025 | $1B | -10% |
| Q1 2025 | $1B | -12% |
| Q4 2024 | $972M | -19% |
BLMN's revenue fell from its 2023 peak and has held roughly level since: $944M last quarter, up 1.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2% | +5.9 points |
| Q2 2026 | 3.8% | +0.8 points |
| Q1 2026 | 5.6% | +0.1 points |
| Q4 2025 | -1.4% | -3 points |
| Q3 2025 | -3.9% | -5.6 points |
| Q2 2025 | 3% | -1.2 points |
| Q1 2025 | 5.5% | -1 points |
| Q4 2024 | 1.7% | -3.1 points |
BLMN has the edge over LCID on profitability, with a higher operating margin.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over BLMN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
BLMN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$39.2M | -$33.5M |
| Q2 2026 | $46.9M | +321% |
| Q1 2026 | $50.1M | +81% |
| Q4 2025 | $63.7M | -35% |
| Q3 2025 | -$5.7M | +$69.2M |
| Q2 2025 | $11.1M | +$35.4M |
| Q1 2025 | $27.7M | +211% |
| Q4 2024 | $97.7M | +58% |
BLMN has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
BLMN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -587K shares |
| 1 year | +0.6% | +543K shares |
| 3 years | -13% | -12.9M shares |
| 5 years | -21% | -22.1M shares |
| Available history | -4.6% | -4.1M shares |
BLMN has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $18.2M |
| Q2 2024 | $14.6M |
| Q1 2024 | $232.9M |
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
BLMN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.4x | Moderate |
| Q2 2026 | 2.8x | Moderate |
| Q1 2026 | 3.1x | Elevated |
| Q4 2025 | 3.4x | Elevated |
| Q3 2025 | 4.0x | Elevated |
| Q2 2025 | 3.0x | Elevated |
| Q1 2025 | 2.8x | Moderate |
| Q4 2024 | 2.9x | Moderate |
BLMN's net debt is about 2.4 years of its operating earnings (EBITDA), down from 4.0 years a year ago.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
BLMN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.2 | Neutral |
| Stochastic | 53.6 | Neutral |
BLMN's weekly RSI is 56 (neutral) and its Stochastic is 54 (neutral).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
BLMN PE vs Consumer Cyclical Sector
| Metric | BLMN | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 18x | 32% below |
| PE % | 31 | 47 | 16 pts below |
BLMN is trading at 12x earnings, a 32% discount to the Consumer Cyclical sector's median of 18x.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
BLMN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.32 | 8.6% above |
| 20 week MA | $9.35 | 8.2% above |
| 50 week MA | $7.86 | 29% above |
| 100 week MA | $8.25 | 23% above |
| 200 week MA | $15.7 | 36% below |
BLMN has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
BLMN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.7 | $19.0 | -13% |
| 2021 | $19.0 | $21.0 | +11% |
| 2022 | $21.0 | $21.0 | 0% |
| 2023 | $21.0 | $28.2 | +34% |
| 2024 | $28.2 | $12.3 | -56% |
| 2025 | $12.3 | $6.79 | -45% |
| 2026 YTD | $6.79 | $10.1 | +49% |
BLMN has the edge over LCID on returns for 2026, with the stronger performance.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.